1-4 of 4
Franziska Behrenbeck
Close
Sort by
Journal Articles

Characteristics of DNMT3A- R882 Mutation in AML

Olga Blau, MD PhD, Franziska Behrenbeck, Mirgul Bayanova, MD, Igor-Wolfgang Blau, MD PhD, Lars Bullinger, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5263.
https://doi.org/10.1182/blood-2018-99-116652
Published: 2018
Journal Articles

DNMT3A expression Analysis in AML

Yubin Xing, MD, Franziska Behrenbeck, Mirgul Bayanova, MD, Igor Blau, MD PhD, Lars Bullinger, MD, Olga Blau, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5276.
https://doi.org/10.1182/blood-2018-99-113626
Published: 2018
Journal Articles

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Olga Blau, MD PhD, Irina Martynkevich, MD PhD, Franziska Behrenbeck, Claudia D. Baldus, MD, Ekaterina Motiko, Sergei Voloshin, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dorken, MD PhD, Igor Wolfgang Blau, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5111.
https://doi.org/10.1182/blood.V130.Suppl_1.5111.5111
Published: 2017
Journal Articles

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

Olga Blau, MD PhD, Franziska Behrenbeck, Nikola Suckert, Lars R. Fransecky, MD, Claudia D. Baldus, MD, Renate Arnold, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2891.
https://doi.org/10.1182/blood.V128.22.2891.2891
Published: 2016